Navigation Links
FDA: New Warnings Required on Use of Gadolinium-Based Contrast Agents
Date:9/9/2010

SILVER SPRING, Md., Sept. 9 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is administered to certain patients with kidney disease.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Three of the GBCAs – Magnevist, Omniscan, and Optimark – will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease. All GBCA labels will emphasize the need to screen patients to detect these types of kidney dysfunction before administration.

GBCAs are intravenous drugs approved by the FDA for use with magnetic resonance imaging or magnetic resonance angiography to help detect abnormalities of body organs, blood vessels, and other tissues.

NSF is a condition involving the formation of excess fibrous connective tissue in the skin, joints, eyes, and internal organs. Symptoms of NSF can include scaling, hardening and tightening of the skin, red or dark patches on the skin, and stiffness. NSF may lead to death, especially if it involves body organs.

The FDA's review of the safety of the most widely used GBCAs determined that Magnevist, Omniscan, and Optimark are associated with a greater risk than other GBCAs for NSF in certain patients with kidney disease. Data suggest that NSF may follow the administration of any GBCA and the FDA continues to assess the safety of each GBCA to better estimate its NSF risks.

"The FDA is requiring these labeling changes to enhance the safe use of gadolinium-based contrast agents, including avoidance of certain agents among patients at highest risk for nephrogenic systemic fibrosis," said Rafel (Dwaine) Rieves, M.D., director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research.

To further enhance the safe use of the imaging agents, the FDA recommends that health care professionals:

  • Estimate kidney function through laboratory testing for patients at risk for chronically reduced kidney function
  • Avoid use of GBCAs in patients suspected or known to have impaired drug elimination unless the imaging is essential and not available without contrast
  • Monitor for signs and symptoms of NSF if a GBCA is administered to a patient with acute kidney injury or chronic, severe kidney disease
  • Administer a GBCA only once during an imaging session

Magnevist is marketed by Bayer Healthcare, Omniscan by GE Healthcare, and Optimark by Covidien.

For more information:

Gadolinium Safety Announcement

http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm

Questions and Answers on Gadolinium-Based Contrast Agents

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142889.htm

Media Inquiries: Karen Riley, 301-796-4674; karen.riley@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
2. PTCB Certification Required for Pharmacy Technician Employment by Department of Veterans Affairs
3. Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
6. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
7. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
8. Federal Agents Seize FastSize Extenders and FastSize EQM™ Erectile Quality Monitors
9. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
10. Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
11. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Md. , Jan. 24, 2017   Intrexon Corporation ... engineering and industrialization of biology to improve the quality of ... has entered into a definitive agreement to acquire GenVec, ... and pioneer in the development of AdenoVerse™ gene delivery technology.  ... GenVec,s expertise in adenoviral vectors and cGMP drug product manufacturing ...
(Date:1/24/2017)... , Jan. 24, 2017   QR ... biopharmaceutical company developing novel therapies for the treatment ... announced the appointment of four world-class key opinion ... new appointments join QR Pharma,s previous roster of ... and direction to support the development of the ...
(Date:1/24/2017)... Research and Markets has announced the addition of the "Optogenetics ... report to their offering. ... Global Optogenetics Market is poised to grow at ... approximately $76.24 million by 2025. Some of the prominent ... using optogentic techniques for neurosciences, quick growth ultrafast laser tools technology, ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... The health insurance industry is ... (AEP) and the Open Enrollment Period (OEP). 2016 was no exception. If anything, ... witnessing higher deductibles, rising premiums, and few choices with their insurance, which is ...
(Date:1/24/2017)... ... , ... The Cruise Web Inc. was recognized today as Northeast ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards are ... on overall business growth in revenue and guests and continuous partnership support and innovative ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide leader ... distribution partnership with Byers Scientific & Manufacturing , a leading designer, engineer ... agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific & ...
(Date:1/24/2017)... Hill, N.C. (PRWEB) , ... January 24, 2017 ... ... Trump Administration is the focus of a new report from the Frank ... Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified concrete ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, 2017 ... the nation’s foremost water advocate and host of the nationally syndicated The Sharon ... America, once again welcomed one of her favorite guests and colleagues, Dr. Gerald ...
Breaking Medicine News(10 mins):